A major British study allays lingering fears that the triptan drugs widely prescribed for migraine headaches might increase the risk of stroke, heart attack and other cardiovascular diseases."We find that triptan treatment in migraine does not increase the risk of stroke, myocardial infarction [heart attack], cardiovascular death, ischemic heart disease or mortality,” says Gillian C. Hall, a consulting neurologist in private practice and lead author of a report on the study in the February issue of Neurology.
